Peroxisome proliferator-activated receptor 3D structures
From Proteopedia
(Difference between revisions)
| Line 11: | Line 11: | ||
**[[1kkq]] – hPPARα + GW6471 Antagonist + SMRT<br /> | **[[1kkq]] – hPPARα + GW6471 Antagonist + SMRT<br /> | ||
**[[2p54]] - hPPARα + NCOA1<br /> | **[[2p54]] - hPPARα + NCOA1<br /> | ||
| + | **[[5azt]] - hPPARα (mutant) + NCOA1 peptide<br /> | ||
**[[2rew]] - hPPARα + azetidinone derivative activator<br /> | **[[2rew]] - hPPARα + azetidinone derivative activator<br /> | ||
**[[2znn]], [[2zno]], [[2znp]], [[2znq]], [[3kdu]], [[3vi8]], [[1i7g]], [[4bcr]], [[5hyk]] - hPPARα + agonist<br /> | **[[2znn]], [[2zno]], [[2znp]], [[2znq]], [[3kdu]], [[3vi8]], [[1i7g]], [[4bcr]], [[5hyk]] - hPPARα + agonist<br /> | ||
| Line 24: | Line 25: | ||
**[[7bpy]], [[7bpz]], [[7bq0]], [[7bq1]], [[7bq2]], [[7bq3]], [[7bq4]] - hPPARα + NCOA1 + ampiphatic carboxylic acid derivative<br /> | **[[7bpy]], [[7bpz]], [[7bq0]], [[7bq1]], [[7bq2]], [[7bq3]], [[7bq4]] - hPPARα + NCOA1 + ampiphatic carboxylic acid derivative<br /> | ||
**[[6l38]] - hPPARα + benzamide derivative<br /> | **[[6l38]] - hPPARα + benzamide derivative<br /> | ||
| + | **[[8hun]], [[8huo]] - hPPARα + anti-NASH drug<br /> | ||
**[[6kyp]], [[6l36]], [[6l37]] - hPPARα + benzamide derivative + propanoic acid derivative <br /> | **[[6kyp]], [[6l36]], [[6l37]] - hPPARα + benzamide derivative + propanoic acid derivative <br /> | ||
| + | **[[8huq]], [[8huk]], [[8hum]] - hPPARα + NCOA1 peptide + anti-NASH drug<br /> | ||
| + | |||
**[[5azt]] - hPPARα (mutant) + NCOA1 peptide<br /> | **[[5azt]] - hPPARα (mutant) + NCOA1 peptide<br /> | ||
*'''PPARγ''';Ligand-binding domain 202-475 | *'''PPARγ''';Ligand-binding domain 202-475 | ||
| - | **[[3prg]], [[2qmv]], [[1prg]], [[6l8b]], [[6vzo]] – hPPARγ<br /> | + | **[[3prg]], [[2qmv]], [[1prg]], [[6l8b]], [[6vzo]], [[8cpj]] – hPPARγ<br /> |
| - | **[[6fzy]], [[6fzg]], [[6t1s]], [[6vzn]], [[7cxe]] - hPPARγ (mutant) <br /> | + | **[[6fzy]], [[6fzg]], [[6t1s]], [[6vzn]], [[7cxe]], [[7e2o]] - hPPARγ (mutant) <br /> |
| - | **[[2zk0]], [[2zk1]], [[2zk2]], [[2zk3]], [[2zk4]], [[2zk5]], [[2zk6]], [[3vjh]], [[3vji]], [[4e4k]], [[4e4q]], [[4jl4]], [[5hzc]], [[4ci5]], [[4ci4]], [[6an1]], [[2f4b]], [[1zeo]], [[2ath]], [[2hwq]], [[2hwr]], [[2i4j]], [[2q59]], [[2q8s]], [[3b3k]], [[3bc5]], [[3cds]], [[3g9e]], [[3gbk]], [[3gz9]], [[3ia6]], [[3kdt]], [[3an3]], [[3an4]], [[3noa]], [[3r5n]], [[3r8a]], [[3vso]], [[3vsp]], [[2xkw]], [[3b0q]], [[3ho0]], [[3hod]], [[1knu]], [[1i7i]], [[1nyx]], [[2pob]], [[5azv]], [[6f2l]], [[6c5t]], [[6c5q]], [[5wr1]], [[5wr0]], [[5wqx]], [[6md2]], [[6md4]], [[6md1]], [[6md0]], [[6mcz]], [[6k0t]], [[6avi]], [[6aug]], [[6qj5]], [[6t9c]], [[6tdc]], [[6vzl]], [[7lot]], [[7jqg]] – hPPARγ + ligand <br /> | + | **[[2zk0]], [[2zk1]], [[2zk2]], [[2zk3]], [[2zk4]], [[2zk5]], [[2zk6]], [[3vjh]], [[3vji]], [[4e4k]], [[4e4q]], [[4jl4]], [[5hzc]], [[4ci5]], [[4ci4]], [[6an1]], [[2f4b]], [[1zeo]], [[2ath]], [[2hwq]], [[2hwr]], [[2i4j]], [[2q59]], [[2q8s]], [[3b3k]], [[3bc5]], [[3cds]], [[3g9e]], [[3gbk]], [[3gz9]], [[3ia6]], [[3kdt]], [[3an3]], [[3an4]], [[3noa]], [[3r5n]], [[3r8a]], [[3vso]], [[3vsp]], [[2xkw]], [[3b0q]], [[3ho0]], [[3hod]], [[1knu]], [[1i7i]], [[1nyx]], [[2pob]], [[5azv]], [[6f2l]], [[6c5t]], [[6c5q]], [[5wr1]], [[5wr0]], [[5wqx]], [[6md2]], [[6md4]], [[6md1]], [[6md0]], [[6mcz]], [[6k0t]], [[6avi]], [[6aug]], [[6qj5]], [[6t9c]], [[6tdc]], [[6vzl]], [[7lot]], [[7jqg]], [[7wox]] – hPPARγ + ligand <br /> |
**[[4l98]], [[4l96]] - hPPARγ (mutant) + ligand<br /> | **[[4l98]], [[4l96]] - hPPARγ (mutant) + ligand<br /> | ||
**[[3r8i]] - hPPARγ + ureidofibrate derivative<br /> | **[[3r8i]] - hPPARγ + ureidofibrate derivative<br /> | ||
**[[6o67]], [[6o68]], [[6dgr]], [[6dgq]], [[6dgo]], [[6dgl]], [[6d8x]], [[6c1i]] - hPPARγ + agonist<br /> | **[[6o67]], [[6o68]], [[6dgr]], [[6dgq]], [[6dgo]], [[6dgl]], [[6d8x]], [[6c1i]] - hPPARγ + agonist<br /> | ||
| - | **[[2g0h]], [[2g0g]], [[2i4p]], [[2i4z]], [[2q5g]], [[2q5p]], [[2q5s]], [[2q61]], [[2q6r]], [[3cdp]], [[3d6d]], [[4em9]], [[4ema]], [[4prg]], [[2q6s]], [[5f9b]], [[4yt1]], [[3wmh]], [[6d3e]], [[6l89]] | + | **[[2g0h]], [[2g0g]], [[2i4p]], [[2i4z]], [[2q5g]], [[2q5p]], [[2q5s]], [[2q61]], [[2q6r]], [[3cdp]], [[3d6d]], [[4em9]], [[4ema]], [[4prg]], [[2q6s]], [[5f9b]], [[4yt1]], [[3wmh]], [[6d3e]], [[6l89]], [[7p4e]], [[8dsz]] - hPPARγ + partial agonist<br /> |
| + | **[[7sqb, [[8dsy]] hPPARγ + inverse agonist<br /> | ||
**[[2om9]] - hPPARγ + cannabinoid<br /> | **[[2om9]] - hPPARγ + cannabinoid<br /> | ||
**[[3b0r]], [[5lsg]], [[4r6s]], [[4r2u]], [[4r06]], [[6dh9]], [[6dcu]], [[6dbh]] - hPPARγ + antagonist<br /> | **[[3b0r]], [[5lsg]], [[4r6s]], [[4r2u]], [[4r06]], [[6dh9]], [[6dcu]], [[6dbh]] - hPPARγ + antagonist<br /> | ||
**[[3osi]], [[3osw]], [[3pba]] - hPPARγ + bisphenol derivative<br /> | **[[3osi]], [[3osw]], [[3pba]] - hPPARγ + bisphenol derivative<br /> | ||
| - | **[[2p4y]], [[3adt]], [[3adu]], [[3adw]], [[3et3]], [[2hfp]], [[3ty0]], [[5two]], [[6fzj]], [[6t6b]], [[6y3u]], [[7a7h]] - hPPARγ + modulator<br /> | + | **[[2p4y]], [[3adt]], [[3adu]], [[3adw]], [[3et3]], [[2hfp]], [[3ty0]], [[5two]], [[6fzj]], [[6t6b]], [[6y3u]], [[7a7h]], [[8aty]], [[8atz]], [[8cph]], [[8cpi]] - hPPARγ + modulator<br /> |
**[[2zvt]] - hPPARγ (mutant) + modulator<br /> | **[[2zvt]] - hPPARγ (mutant) + modulator<br /> | ||
| - | **[[2vsr]], [[2vst]], [[2vv0]], [[2vv1]], [[2vv2]], [[2vv3]], [[2vv4]], [[3x1i]], [[3x1h]], [[3wj5]], [[3wj4]], [[3po9]], [[3sz1]] - hPPARγ + fatty acid activator<br /> | + | **[[2vsr]], [[2vst]], [[2vv0]], [[2vv1]], [[2vv2]], [[2vv3]], [[2vv4]], [[3x1i]], [[3x1h]], [[3wj5]], [[3wj4]], [[3po9]], [[3sz1]], [[8bf2]], [[8bff]] - hPPARγ + fatty acid activator<br /> |
**[[6jey]] - hPPARγ + fatty acid<br /> | **[[6jey]] - hPPARγ + fatty acid<br /> | ||
**[[6jf0]], [[7efq]] - hPPARγ + fluorescent probe<br /> | **[[6jf0]], [[7efq]] - hPPARγ + fluorescent probe<br /> | ||
| Line 55: | Line 60: | ||
**[[6zly]] - hPPARγ + valine derivative <br /> | **[[6zly]] - hPPARγ + valine derivative <br /> | ||
| - | * | + | **[[7qb1]], [[8adf]], [[8c0c]], [[8dkv]] - hPPARγ + inhibitor<br /> |
| + | **[[8hup]] - hPPARg + NCOA1 peptide + anti-NASH drug<br /> | ||
| - | * | + | *PPARγ complex with NCAO1 |
| - | **[[ | + | |
| - | + | **[[2gtk]], [[3qt0]], [[5gtp]], [[5gto]], [[5gtn]], [[5ycp]], [[5ycn]], [[5z6s]], [[5z5s]], [[6dgp]], [[6ilq]], [[6ijs]], [[6ijr]], [[6icj]], [[6jq7]], [[6ktm]], [[7cxf]] - hPPARγ + NCOA1 peptide<br /> | |
| - | + | ||
**[[6t1v]], [[7cxg]], [[7cxh]], [[7cxi]], [[7cxj]], [[7cxk]], [[7cxl]] - hPPARγ (mutant) + NCOA1 peptide<br /> | **[[6t1v]], [[7cxg]], [[7cxh]], [[7cxi]], [[7cxj]], [[7cxk]], [[7cxl]] - hPPARγ (mutant) + NCOA1 peptide<br /> | ||
**[[6ktn]] - hPPARγ (mutant) + NCOA1 peptide + leukemia drug<br /> | **[[6ktn]] - hPPARγ (mutant) + NCOA1 peptide + leukemia drug<br /> | ||
| - | + | **[[3fur]], [[3kmg]], [[3v9t]], [[3v9v]], [[3v9y]], [[4f9m]], [[3b1m]], [[3lmp]], [[6fzp]], [[8dk4]] - hPPARγ + NCOA1+ modulator<br /> | |
| - | + | ||
| - | + | ||
| - | **[[3fur]], [[3kmg]], [[3v9t]], [[3v9v]], [[3v9y]], [[4f9m]], [[3b1m]], [[3lmp]], [[6fzp]] - hPPARγ + | + | |
**[[6fzf]] - hPPARγ (mutant) + NCOA1+ modulator<br /> | **[[6fzf]] - hPPARγ (mutant) + NCOA1+ modulator<br /> | ||
**[[4fgy]], [[2prg]] - hPPARγ + antidiabetic drug + NCOA1 peptide<br /> | **[[4fgy]], [[2prg]] - hPPARγ + antidiabetic drug + NCOA1 peptide<br /> | ||
| - | **[[ | + | **[[7wgo]], [[7wgq]] - hPPARγ + hyperlipidaemia drug + NCOA1 peptide<br /> |
| + | **[[7wgp]] - hPPARγ + pancreatitis drug + NCOA1 peptide<br /> | ||
**[[6ad9]] - hPPARγ + anticancer agent + NCOA1 peptide<br /> | **[[6ad9]] - hPPARγ + anticancer agent + NCOA1 peptide<br /> | ||
| - | **[[6izm]], [[6izn]] - hPPARγ + pyridine derivative + NCOA1 peptide<br /> | + | **[[6izm]], [[6izn]], [[8dkn]] - hPPARγ + pyridine derivative + NCOA1 peptide<br /> |
**[[3s9s]], [[3t03]], [[2fvj]]- hPPARγ + NCOA1 peptide + partial agonist<br /> | **[[3s9s]], [[3t03]], [[2fvj]]- hPPARγ + NCOA1 peptide + partial agonist<br /> | ||
**[[4y29]], [[2fvj]], [[5azt]] - hPPARγ + NCOA1 peptide + ligand<br /> | **[[4y29]], [[2fvj]], [[5azt]] - hPPARγ + NCOA1 peptide + ligand<br /> | ||
| - | **[[3h0a]] - hPPARγ + | + | **[[3h0a]] - hPPARγ + NCOA1 + retinoic acid receptor + retinoic acid + partial agonist<br /> |
| - | **[[1k74]], [[1rdt]], [[1fm9]] - hPPARγ + NCOA1 + retinoic acid receptor | + | **[[1k74]], [[1rdt]], [[1fm9]] - hPPARγ + NCOA1 + retinoic acid receptor + retinoic acid + agonist<br /> |
**[[5ji0]] - hPPARγ + retinoic acid receptor + NCOA1 peptide + antidiabetic drug <br /> | **[[5ji0]] - hPPARγ + retinoic acid receptor + NCOA1 peptide + antidiabetic drug <br /> | ||
| - | **[[3dzu]], [[3e00]], [[3dzy]] - hPPARγ + DNA + retinoic acid receptor α + NCOA2 peptide + retinoic acid<br /> | ||
| - | **[[1fm6]] - hPPARγ + antidiabetic drug + retinoic acid receptor α + NCOA2 peptide + retinoic acid<br /> | ||
**[[3vn2]], [[4hee]], [[4prg]] - hPPARγ + NCOA1 peptide + activator<br /> | **[[3vn2]], [[4hee]], [[4prg]] - hPPARγ + NCOA1 peptide + activator<br /> | ||
| + | |||
| + | * PPARγ complex with NCAO2 | ||
| + | |||
| + | **[[1wm0]] – hPPARγ + NCAO2 peptide + agonist<br /> | ||
| + | **[[5dwl]], [[5dvc]], [[5dv8]], [[5dv6]], [[5dv3]], [[5dsh]] - hPPARγ + NCAO2 peptide + inhibitor<br /> | ||
| + | **[[7sqa]], [[8aqm]], [[8aqn]], [[8b8w]], [[8b8x]], [[8b8y]], [[8b90]], [[8b92]], [[8b93]], [[8b94]], [[8b95]]- hPPARγ + NCOA2 peptide + inverse agonist<br /> | ||
| + | **[[8b8z]], [[8b91]] - hPPARγ (mutant) + NCOA2 peptide + inverse agonist<br /> | ||
| + | **[[3dzu]], [[3e00]], [[3dzy]] - hPPARγ + DNA + retinoic acid receptor + NCOA2 peptide + retinoic acid<br /> | ||
| + | **[[1fm6]] - hPPARγ + antidiabetic drug + retinoic acid receptor + NCOA2 peptide + retinoic acid<br /> | ||
| + | |||
| + | * PPARγ complex with other proteins | ||
| + | |||
| + | **[[1zgy]] – hPPARγ + antidiabetic drug + nuclear receptor peptide<br /> | ||
| + | **[[3cs8]], [[3u9q]], [[8bf1]] - hPPARγ + PGC-1A peptide<br /> | ||
| + | **[[3cwd]] - hPPARγ + SRC1-2<br /> | ||
| + | **[[6oni]], [[6pdz]] - hPPARγ +inverse agonist + NCOR peptide<br /> | ||
**[[6ms7]] - hPPARγ + PGC1 LXXLL + modulator<br /> | **[[6ms7]] - hPPARγ + PGC1 LXXLL + modulator<br /> | ||
| - | **[[6dgp]], [[5z6s]], [[5z5s]] - hPPARγ + coactivator peptide<br /> | ||
**[[6d94]] - hPPARγ + mediator of RNA polymerase II peptide<br /> | **[[6d94]] - hPPARγ + mediator of RNA polymerase II peptide<br /> | ||
**[[6onj]] - hPPARγ + mediator of RNA polymerase II peptide + antidiabetic drug<br /> | **[[6onj]] - hPPARγ + mediator of RNA polymerase II peptide + antidiabetic drug<br /> | ||
| + | **[[7rle]] - hPPARγ + CREB-binding protein peptide + agonist<br /> | ||
*'''PPARδ''';Ligand-binding domain 171-441 | *'''PPARδ''';Ligand-binding domain 171-441 | ||
| Line 93: | Line 110: | ||
**[[3dy6]] – hPPARδ + anthranilic acid <br /> | **[[3dy6]] – hPPARδ + anthranilic acid <br /> | ||
**[[3et2]], [[1gwx]] – hPPARδ + fatty acid<br /> | **[[3et2]], [[1gwx]] – hPPARδ + fatty acid<br /> | ||
| - | **[[2j14]], [[2xyj]], [[2xyw]], [[2xyx]], [[3oz0]], [[3sp9]], [[5u3q]], [[5u3r]], [[5u3s]], [[5u3t]], [[5u3u]], [[5u3v]], [[5u3w]], [[5u3x]], [[5u3y]], [[5u3z]], [[5u40]], [[5u41]], [[5u42]], [[5u43]], [[5u44]], [[5u45]], [[1gwx]], [[3tkm]], [[1y0s]], [[5u46]], [[5y7x]] - hPPARδ + agonist<br /> | + | **[[2j14]], [[2xyj]], [[2xyw]], [[2xyx]], [[3oz0]], [[3sp9]], [[5u3q]], [[5u3r]], [[5u3s]], [[5u3t]], [[5u3u]], [[5u3v]], [[5u3w]], [[5u3x]], [[5u3y]], [[5u3z]], [[5u40]], [[5u41]], [[5u42]], [[5u43]], [[5u44]], [[5u45]], [[1gwx]], [[3tkm]], [[1y0s]], [[5u46]], [[5y7x]], [[7vwf]], [[7vwg]], [[7vwh]], [[7w0g]], [[7wgn]], [[8hul]] - hPPARδ + agonist<br /> |
**[[3peq]] - hPPARδ + partial agonist<br /> | **[[3peq]] - hPPARδ + partial agonist<br /> | ||
**[[3d5f]] - hPPARδ + phenoxy derivative<br /> | **[[3d5f]] - hPPARδ + phenoxy derivative<br /> | ||
| - | **[[5xmx]], [[6a6p]], [[5zxi]] - hPPARδ + inhibitor<br /> | + | **[[5xmx]], [[6a6p]], [[5zxi]], [[7f80]] - hPPARδ + inhibitor<br /> |
| + | **[[7wgl]] - hPPARd + hyperlipidaemia drug <br /> | ||
}} | }} | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 09:10, 23 August 2023
3D Structures of PPAR
Updated on 23-August-2023 {{#tree:id=OrganizedByTopic|openlevels=0|
- PPARα;Ligand-binding domain 201-468
- 1k7l – hPPARα + G2409544 + NCOA1 - human
- 3e94 – hPPARα + fatty acid activator
- 4bcr, 5hyk - hPPARα + ligand
- 1kkq – hPPARα + GW6471 Antagonist + SMRT
- 2p54 - hPPARα + NCOA1
- 5azt - hPPARα (mutant) + NCOA1 peptide
- 2rew - hPPARα + azetidinone derivative activator
- 2znn, 2zno, 2znp, 2znq, 3kdu, 3vi8, 1i7g, 4bcr, 5hyk - hPPARα + agonist
- 3fei, 3fej, 3g8i, 3sp6, 6l96 - hPPARα + agonist + NCOA1 peptide
- 3sp6 - hPPARα + hPPARγ peptide + agonist
- 6kxx, 6kxy - hPPARα + peptide + agonist
- 7c6q - hPPARα + peptide + sanguinarine
- 3et1 - hPPARα + NCOA1 + indole derivative
- 6kb7, 6kba - hPPARα + pyrimidine derivative
- 7e5f, 7e5g, 7e5h, 7e5i - hPPARα + propanoic acid derivative
- 2npa - hPPARα + propanoic acid derivative + NCOA1
- 6jey, 6kax, 6kay, 6kaz ,6kb0, 6kb1, 6kb2, 6kb3, 6kb4 ,6kb5, 6kb6 ,6kb8, 6kb9, 6lx4, 6lx5, 6lx6, 6lx7, 6lx8, 6lx9, 6lxa, 6lxb, 6lxc - hPPARα + ampiphatic carboxylic acid derivative
- 7bpy, 7bpz, 7bq0, 7bq1, 7bq2, 7bq3, 7bq4 - hPPARα + NCOA1 + ampiphatic carboxylic acid derivative
- 6l38 - hPPARα + benzamide derivative
- 8hun, 8huo - hPPARα + anti-NASH drug
- 6kyp, 6l36, 6l37 - hPPARα + benzamide derivative + propanoic acid derivative
- 8huq, 8huk, 8hum - hPPARα + NCOA1 peptide + anti-NASH drug
- 1k7l – hPPARα + G2409544 + NCOA1 - human
- 5azt - hPPARα (mutant) + NCOA1 peptide
- 5azt - hPPARα (mutant) + NCOA1 peptide
- PPARγ;Ligand-binding domain 202-475
- 3prg, 2qmv, 1prg, 6l8b, 6vzo, 8cpj – hPPARγ
- 6fzy, 6fzg, 6t1s, 6vzn, 7cxe, 7e2o - hPPARγ (mutant)
- 2zk0, 2zk1, 2zk2, 2zk3, 2zk4, 2zk5, 2zk6, 3vjh, 3vji, 4e4k, 4e4q, 4jl4, 5hzc, 4ci5, 4ci4, 6an1, 2f4b, 1zeo, 2ath, 2hwq, 2hwr, 2i4j, 2q59, 2q8s, 3b3k, 3bc5, 3cds, 3g9e, 3gbk, 3gz9, 3ia6, 3kdt, 3an3, 3an4, 3noa, 3r5n, 3r8a, 3vso, 3vsp, 2xkw, 3b0q, 3ho0, 3hod, 1knu, 1i7i, 1nyx, 2pob, 5azv, 6f2l, 6c5t, 6c5q, 5wr1, 5wr0, 5wqx, 6md2, 6md4, 6md1, 6md0, 6mcz, 6k0t, 6avi, 6aug, 6qj5, 6t9c, 6tdc, 6vzl, 7lot, 7jqg, 7wox – hPPARγ + ligand
- 4l98, 4l96 - hPPARγ (mutant) + ligand
- 3r8i - hPPARγ + ureidofibrate derivative
- 6o67, 6o68, 6dgr, 6dgq, 6dgo, 6dgl, 6d8x, 6c1i - hPPARγ + agonist
- 2g0h, 2g0g, 2i4p, 2i4z, 2q5g, 2q5p, 2q5s, 2q61, 2q6r, 3cdp, 3d6d, 4em9, 4ema, 4prg, 2q6s, 5f9b, 4yt1, 3wmh, 6d3e, 6l89, 7p4e, 8dsz - hPPARγ + partial agonist
- [[7sqb, 8dsy hPPARγ + inverse agonist
- 2om9 - hPPARγ + cannabinoid
- 3b0r, 5lsg, 4r6s, 4r2u, 4r06, 6dh9, 6dcu, 6dbh - hPPARγ + antagonist
- 3osi, 3osw, 3pba - hPPARγ + bisphenol derivative
- 2p4y, 3adt, 3adu, 3adw, 3et3, 2hfp, 3ty0, 5two, 6fzj, 6t6b, 6y3u, 7a7h, 8aty, 8atz, 8cph, 8cpi - hPPARγ + modulator
- 2zvt - hPPARγ (mutant) + modulator
- 2vsr, 2vst, 2vv0, 2vv1, 2vv2, 2vv3, 2vv4, 3x1i, 3x1h, 3wj5, 3wj4, 3po9, 3sz1, 8bf2, 8bff - hPPARγ + fatty acid activator
- 6jey - hPPARγ + fatty acid
- 6jf0, 7efq - hPPARγ + fluorescent probe
- 6mcz, 6md0, 6md1, 6md2, 6qj5, 6t9c - hPPARγ + ligand
- 6tsg - hPPARγ + hormone
- 3ads, 3adx, 5u5l, 4xum, 4xuh, 4xta, 4xld, 6d5a, 6o67, 6o68, 7ahj, 7awc, 7awd, 7e0a - hPPARγ + anti-inflammatory drug
- 4oj4 - hPPARγ (mutant) + anti-inflammatory drug
- 3adv - hPPARγ + serotonin
- 3k8s, 3et0, 2yfe, 4a4v, 4a4w, 4jaz, 5tto, 4pwl, 4pvu, 5y2t, 5y2o, 5ugm, 6dha - hPPARγ + antidiabetic drug
- 4o8f, 6vzm - hPPARγ (mutant) + antidiabetic drug
- 6md4 - hPPARγ + oleic acid + antidiabetic drug
- 6enq - hPPARγ + antifibrotic drug
- 6zly - hPPARγ + valine derivative
- 3prg, 2qmv, 1prg, 6l8b, 6vzo, 8cpj – hPPARγ
- PPARγ complex with NCAO1
- 2gtk, 3qt0, 5gtp, 5gto, 5gtn, 5ycp, 5ycn, 5z6s, 5z5s, 6dgp, 6ilq, 6ijs, 6ijr, 6icj, 6jq7, 6ktm, 7cxf - hPPARγ + NCOA1 peptide
- 6t1v, 7cxg, 7cxh, 7cxi, 7cxj, 7cxk, 7cxl - hPPARγ (mutant) + NCOA1 peptide
- 6ktn - hPPARγ (mutant) + NCOA1 peptide + leukemia drug
- 3fur, 3kmg, 3v9t, 3v9v, 3v9y, 4f9m, 3b1m, 3lmp, 6fzp, 8dk4 - hPPARγ + NCOA1+ modulator
- 6fzf - hPPARγ (mutant) + NCOA1+ modulator
- 4fgy, 2prg - hPPARγ + antidiabetic drug + NCOA1 peptide
- 7wgo, 7wgq - hPPARγ + hyperlipidaemia drug + NCOA1 peptide
- 7wgp - hPPARγ + pancreatitis drug + NCOA1 peptide
- 6ad9 - hPPARγ + anticancer agent + NCOA1 peptide
- 6izm, 6izn, 8dkn - hPPARγ + pyridine derivative + NCOA1 peptide
- 3s9s, 3t03, 2fvj- hPPARγ + NCOA1 peptide + partial agonist
- 4y29, 2fvj, 5azt - hPPARγ + NCOA1 peptide + ligand
- 3h0a - hPPARγ + NCOA1 + retinoic acid receptor + retinoic acid + partial agonist
- 1k74, 1rdt, 1fm9 - hPPARγ + NCOA1 + retinoic acid receptor + retinoic acid + agonist
- 5ji0 - hPPARγ + retinoic acid receptor + NCOA1 peptide + antidiabetic drug
- 3vn2, 4hee, 4prg - hPPARγ + NCOA1 peptide + activator
- 2gtk, 3qt0, 5gtp, 5gto, 5gtn, 5ycp, 5ycn, 5z6s, 5z5s, 6dgp, 6ilq, 6ijs, 6ijr, 6icj, 6jq7, 6ktm, 7cxf - hPPARγ + NCOA1 peptide
- PPARγ complex with NCAO2
- 1wm0 – hPPARγ + NCAO2 peptide + agonist
- 5dwl, 5dvc, 5dv8, 5dv6, 5dv3, 5dsh - hPPARγ + NCAO2 peptide + inhibitor
- 7sqa, 8aqm, 8aqn, 8b8w, 8b8x, 8b8y, 8b90, 8b92, 8b93, 8b94, 8b95- hPPARγ + NCOA2 peptide + inverse agonist
- 8b8z, 8b91 - hPPARγ (mutant) + NCOA2 peptide + inverse agonist
- 3dzu, 3e00, 3dzy - hPPARγ + DNA + retinoic acid receptor + NCOA2 peptide + retinoic acid
- 1fm6 - hPPARγ + antidiabetic drug + retinoic acid receptor + NCOA2 peptide + retinoic acid
- 1wm0 – hPPARγ + NCAO2 peptide + agonist
- PPARγ complex with other proteins
- 1zgy – hPPARγ + antidiabetic drug + nuclear receptor peptide
- 3cs8, 3u9q, 8bf1 - hPPARγ + PGC-1A peptide
- 3cwd - hPPARγ + SRC1-2
- 6oni, 6pdz - hPPARγ +inverse agonist + NCOR peptide
- 6ms7 - hPPARγ + PGC1 LXXLL + modulator
- 6d94 - hPPARγ + mediator of RNA polymerase II peptide
- 6onj - hPPARγ + mediator of RNA polymerase II peptide + antidiabetic drug
- 7rle - hPPARγ + CREB-binding protein peptide + agonist
- 1zgy – hPPARγ + antidiabetic drug + nuclear receptor peptide
- PPARδ;Ligand-binding domain 171-441
- 2gwx – hPPARδ
- 2env – hPPARδ zinc finger domain 72-146 - NMR
- 2baw, 2b50, 2awh – hPPARδ + Vaccenic Acid
- 3gwx – hPPARδ + 5,8,11,14,17-Eicosapentaenoic Acid
- 3dy6 – hPPARδ + anthranilic acid
- 3et2, 1gwx – hPPARδ + fatty acid
- 2j14, 2xyj, 2xyw, 2xyx, 3oz0, 3sp9, 5u3q, 5u3r, 5u3s, 5u3t, 5u3u, 5u3v, 5u3w, 5u3x, 5u3y, 5u3z, 5u40, 5u41, 5u42, 5u43, 5u44, 5u45, 1gwx, 3tkm, 1y0s, 5u46, 5y7x, 7vwf, 7vwg, 7vwh, 7w0g, 7wgn, 8hul - hPPARδ + agonist
- 3peq - hPPARδ + partial agonist
- 3d5f - hPPARδ + phenoxy derivative
- 5xmx, 6a6p, 5zxi, 7f80 - hPPARδ + inhibitor
- 7wgl - hPPARd + hyperlipidaemia drug
- 2gwx – hPPARδ
}}
